Overview |
bsm-54722R |
CD5 Monoclonal Antibody |
WB, IHC-P |
Human |
Specifications |
Unconjugated |
Rabbit |
Synthetic Peptide within N terminal Human CD5. |
Monoclonal |
4H1 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Store at -20°C for 12 months. |
Target |
921 |
P06127 |
Cell membrane |
CD 5 antibody, CD5 antibody, CD5 antigen (p56 62) antibody, CD5 antigen antibody, CD5 molecule antibody, CD5_HUMAN antibody, LEU1 antibody, LyA antibody, Lymphocyte antigen T1/Leu-1 antibody, OTTHUMP00000236973 antibody, T-cell surface glycoprotein CD5 antibody, T1 antibody |
CD5 is a 55kDa T lymphocyte single chain transmembrane glycoprotein. It is present on all mature T lymphocytes, on most thymocytes and on many T cell leukemias and lymphomas. It reacts with a subpopulation of activated B cells. CD5/Lyt1 antigen is a monomeric type I transmembrane glycoprotein expressed on thymocytes, T lymphocytes, and a subset of B lymphocytes, but not on natural killer (NK) cells. It has been identified as the major ligand of the B cell antigen CD72. The frequency of CD5+ B cells exhibits strain dependent variation, and the phenotypic, anatomical, functional, developmental, and pathological characteristics of the CD5+ B cells suggest that they may represent a distinct lineage, known as B1 cells. Binding of CD5 on the T cell surface can augment alloantigen or mitogen induced lymphocyte proliferation and induces increased cytosolic free calcium, IL2 secretion, and IL2R expression. It has been proposed that CD5 negatively regulates signal transduction mediated by the T cell and B cell receptors. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |